The Quotes are Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.

News Headlines and Feed

Business News Videos

Chances of treating resistant bacterial increase with a Swedish breakthrough

Monday, 10 September 2012
There may be increased possibility of treating the hitherto most resistant bacteria NDM, as Swedish researchers at the University of Uppsala have hit a breakthrough.

In a test, for the first time a trail was conducted which had to do with a combination of various antibiotics, which, some of them where idle, but when combined, they made the infection treatable. The results is presented at an international congress of infection in San Francisco, USA on Monday.

Thomas Tängdén, infectious diseases researcher at the Uppsala University Hospital told radio Sweden "we have found new combinations of antibiotics that are effective. Although the bacteria are resistant to individual preparations, one can get a good killing effect on bacteria by combining them. We have lab tested on four bacterial strains and for many of these combinations, it's all there."

What the researchers have done is in effect, make use of the older antibiotics that have been stopped using because of factors such as side effects. Together they have a good effect against the most resistant bacteria NDM and the like.

In Sweden, there are about 20 infected patients with resistance to antibiotics according to statistics from the Infectious Diseases Institute. However, it is still too early to determine whether this can be recommended to the patients with NDM and similar bacteria, according to Thomas Tängdén, for there are also risks.

NDM-1 is an enzyme produced by certain bacteria, which allows them to neutralise the harmful effects of carbapenems, one of the most powerful types of antibiotics available to doctors.

Its origin has been identified from its name. New Delhi metallo-ß-lactamase-1 has also been identified in UK patients who had recently travelled to India or Pakistan for medical treatment - often-cosmetic surgery. When these people were later treated in UK or US hospitals, NDM-1 passed to other patients.

"In general, critically ill patients are often cared for in intensive care. They usually have other underlying diseases that make them to remain in trouble and one do not know how to treat them. So it is a safety all the time. There is a balance between risk and benefit."

Infectious diseases around the world are increasingly facing difficult problems when multi-resistant bacteria spread. Being forced to use treatments that are not sufficiently tested to patients to seeking their survival is unfortunate, according to Professor Otto Cars, speaking to radio Sweden.

"There is too little knowledge. Doctors are forced to experiment without proper scientific support. Here is a great neglected area of research."
And before new treatments may be recommended by the regulatory agencies, there is the need for rigorous testing on people, not only in the test tube, and that is a dilemma," says Otto Cars.

"We will not have neither the time nor the money to wait for new clinical trials, but we must use the knowledge that is made in the laboratory much more," he added.
In places such as India the growing mixture and free available of anti-biotics means the explosion resistance bacteria that would not be treated with traditional anti biotics.
So authorities are also pointing the growing climate change, method of food cultivation and preservation, expansion of economic development even in the developing countries makes the natural environment weaker in assisting in the challenge against bacteria, which have also evolved to counter the changing environment.

Read m ore about NDM here
By Scancomark.com team

What do you think about this article? Would like to leave comments? Join our network!